Published online September 30, 2005
PEDIATRICS Vol. 116 No. 4 October 2005, pp. 989-995 (doi:10.1542/peds.2005-0504)

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Wooditch, A. C. Articles by Aronoff, S. C. Search for Related Content PubMed PubMed Citation Articles by Wooditch, A. C. Articles by Aronoff, S. C. Related Collections Infectious Disease & Immunity Related AAP Red Book topics: Kawasaki Disease (Mucocutaneous... Social Bookmarking                         What's this?

REVIEW ARTICLE

Effect of Initial Corticosteroid Therapy on Coronary Artery Aneurysm Formation in Kawasaki Disease: A Meta-analysis of 862 Children

Angela C. Wooditch, MD, Stephen C. Aronoff, MD

Department of Pediatrics, Temple University School of Medicine, Philadelphia, Pennsylvania

Objective. Kawasaki disease is an acute vasculitis of infancy and childhood. When untreated, 15% to 25% of patients develop coronary artery aneurysms. Although the use of aspirin and intravenous immune globulin (IVIG) as initial therapy is well established, the role of corticosteroids is uncertain. The objective of this study was to identify clinical trials that compared the rate of coronary aneurysm formation after initial therapy with corticosteroids or an appropriate control and to determine the overall efficacy of corticosteroid therapy for the initial treatment of Kawasaki disease.

Methods. Published studies were identified by searches of the Medline and the Cochrane Central Register of Controlled Trials databases as well as hand searches of selected references. Studies were included when (1) all subjects had a stated diagnosis of Kawasaki disease; (2) a corticosteroid preparation was included as part of the initial management of the disease process; (3) a therapeutically matched control group was included for the entire study, or subsets of patients that received a therapeutic intervention identical to the experimental group except for the inclusion of a corticosteroid compound could be identified; and (4) 2-dimensional echocardiography or coronary artery catheterization was performed at least 2 weeks after therapy to detect the presence of coronary aneurysms. Included studies were evaluated for quality and heterogeneity. Meta-analysis was performed using a fixed-effects model.

Results. Eight studies fulfilled criteria for inclusion. Because 2 of these studies provided adequate detail to permit evaluation of 2 subgroups each, a total of 10 groups were available for evaluation. The significant heterogeneity that existed among the 10 studies (Q = 21.9, I² = 59.0) was eliminated when 2 studies with markedly different study designs were removed (Q = 5.59, I² = 0.00). Meta-analysis of the remaining 8 studies revealed a significant reduction in the incidence of coronary artery aneurysms among patients who received corticosteroid therapy plus aspirin ± IVIG compared with aspirin ± IVIG alone (odds ratio [OR] 0.546; 95% confidence interval [CI]: 0.371–0.803); the benefit of corticosteroid therapy was maintained when study subsets of aspirin alone (OR: 0.601; 95% CI: 0.392–0.921) or aspirin + IVIG (OR: 0.352; 95% CI: 0.136–0.909) were compared with matched regimens that contained corticosteroids.

Conclusion. The inclusion of corticosteroids in aspirin-containing regimens for the initial treatment of Kawasaki disease reduces the incidence of coronary aneurysms.

---

Key Words: Kawasaki disease • corticosteroids • coronary aneurysms • complications • therapy

Abbreviations: IVIG, intravenous immunoglobulin • OR, odds ratios • SE, standard error • CI, confidence interval

---

Accepted May 5, 2005.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. P A Ioannidis, N. A Patsopoulos, and E. Evangelou Uncertainty in heterogeneity estimates in meta-analyses BMJ, November 3, 2007; 335(7626): 914 - 916. [Full Text] [PDF]

				P. F. Weiss, J. A. Feinstein, X. Luan, J. M. Burnham, and C. Feudtner Effects of Corticosteroid on Henoch-Schonlein Purpura: A Systematic Review Pediatrics, November 1, 2007; 120(5): 1079 - 1087. [Abstract] [Full Text] [PDF]

				M. J. O'Connor and F. T. Saulsbury Incomplete and Atypical Kawasaki Disease in a Young Infant: Severe, Recalcitrant Disease Responsive to Infliximab Clinical Pediatrics, May 1, 2007; 46(4): 345 - 348. [Abstract] [PDF]

				J. W. Newburger, L. A. Sleeper, B. W. McCrindle, L. L. Minich, W. Gersony, V. L. Vetter, A. M. Atz, J. S. Li, M. Takahashi, A. L. Baker, et al. Randomized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki Disease N. Engl. J. Med., February 15, 2007; 356(7): 663 - 675. [Abstract] [Full Text] [PDF]

				A. K. Attili and P. N. Cascade CT and MRI of Coronary Artery Disease:Evidence-Based Review. Am. J. Roentgenol., December 1, 2006; 187(6 Suppl): S483 - S499. [Abstract] [Full Text] [PDF]

				A. K. Attili, J. M. Foral, U. J. Schoepf, P. N. Cascade, and F. S. Chew CT and MRI of Coronary Artery Disease: Self-Assessment Module Am. J. Roentgenol., December 1, 2006; 187(6_Supplement): S500 - S504. [Abstract] [Full Text] [PDF]

				T. Kobayashi, Y. Inoue, K. Takeuchi, Y. Okada, K. Tamura, T. Tomomasa, T. Kobayashi, and A. Morikawa Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients With Kawasaki Disease Circulation, June 6, 2006; 113(22): 2606 - 2612. [Abstract] [Full Text] [PDF]

				Corticosteroids for Kawasaki Disease? Journal Watch (General), October 25, 2005; 2005(1025): 5 - 5. [Full Text]